WO2012104823A3 - Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives - Google Patents

Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives Download PDF

Info

Publication number
WO2012104823A3
WO2012104823A3 PCT/IB2012/050514 IB2012050514W WO2012104823A3 WO 2012104823 A3 WO2012104823 A3 WO 2012104823A3 IB 2012050514 W IB2012050514 W IB 2012050514W WO 2012104823 A3 WO2012104823 A3 WO 2012104823A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
neurodegenerative diseases
pyridopyrimidinone compounds
pyridopyrimidinone
compounds
Prior art date
Application number
PCT/IB2012/050514
Other languages
English (en)
Other versions
WO2012104823A2 (fr
Inventor
Stefan Frentzel
Paolo Paganetti
Christoph WIESSNER
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2012104823A2 publication Critical patent/WO2012104823A2/fr
Publication of WO2012104823A3 publication Critical patent/WO2012104823A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

La présente invention concerne des composés pyridopyrimidinones de la formule (I) en vue de leur utilisation dans le traitement de maladies neurodégénératives.
PCT/IB2012/050514 2011-02-04 2012-02-03 Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives WO2012104823A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161439740P 2011-02-04 2011-02-04
US61/439,740 2011-02-04

Publications (2)

Publication Number Publication Date
WO2012104823A2 WO2012104823A2 (fr) 2012-08-09
WO2012104823A3 true WO2012104823A3 (fr) 2012-11-29

Family

ID=45757030

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/050514 WO2012104823A2 (fr) 2011-02-04 2012-02-03 Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives

Country Status (1)

Country Link
WO (1) WO2012104823A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2879995T3 (es) 2015-12-10 2021-11-23 Ptc Therapeutics Inc Métodos para el tratamiento de la enfermedad de Huntington
EA201992878A1 (ru) 2017-06-05 2020-05-08 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни хантингтона
BR112019027717A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN112135815A (zh) 2018-03-27 2020-12-25 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
EP3814360A1 (fr) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Composés hétéroaryles pour le traitement de la maladie de huntington
AU2019294478B2 (en) 2018-06-27 2023-03-23 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
CN109846886A (zh) * 2019-03-26 2019-06-07 中国医学科学院基础医学研究所 Nvp-hsp990在制备治疗癫痫的药物中的用途
CN111214473B (zh) * 2020-02-14 2022-02-01 中国人民解放军陆军军医大学 Hsp990在制备抗轮状病毒药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041362A1 (fr) * 2005-09-30 2007-04-12 Novartis Ag 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidine-5-ones
US20100022635A1 (en) * 2008-07-28 2010-01-28 University Of Kansas Heat shock protein 90 inhibitor dosing methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041362A1 (fr) * 2005-09-30 2007-04-12 Novartis Ag 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidine-5-ones
US20100022635A1 (en) * 2008-07-28 2010-01-28 University Of Kansas Heat shock protein 90 inhibitor dosing methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAUDHURY SUBHABRATA ET AL: "Hsp90 as a target for drug developement", CHEMMEDCHEM, WILEY - VCH VERLAG., WEINHEIM, DE, vol. 1, no. 12, 1 December 2006 (2006-12-01), pages 1331 - 1340, XP002467848, ISSN: 1860-7179, DOI: 10.1002/CMDC.200600112 *
LABBADIA JOHN ET AL: "Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease.", THE JOURNAL OF CLINICAL INVESTIGATION AUG 2011 LNKD- DOI:10.1172/JCI57413 PUBMED:21785217, vol. 121, no. 8, August 2011 (2011-08-01), pages 3306 - 3319, XP002684227, ISSN: 1558-8238 *
M. WAZA ET AL: "Alleviating Neurodegeneration by an Anticancer Agent: An Hsp90 Inhibitor (17-AAG)", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1086, no. 1, 1 November 2006 (2006-11-01), pages 21 - 34, XP055039394, ISSN: 0077-8923, DOI: 10.1196/annals.1377.012 *

Also Published As

Publication number Publication date
WO2012104823A2 (fr) 2012-08-09

Similar Documents

Publication Publication Date Title
HRP20190491T1 (hr) Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti
AU2016202437A1 (en) Organic compositions to treat HSF1-related diseases
HK1197400A1 (zh) 治療 的化合物
ZA201403795B (en) Formulations for the treatment of diabetes
HK1201256A1 (en) Pyrrolopyrimidine compounds for the treatment of cancer
AP2014007533A0 (en) Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
WO2012104823A3 (fr) Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives
EP2773342A4 (fr) Compositions utiles pour le traitement de maladies virales
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
HUE037600T2 (hu) Vegyületek és készítmények paraziták által okozott fertõzések kezelésére
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
WO2013178322A8 (fr) Dérivés de spiro-tetrahydro-benzothiophène utilisés pour traiter les maladies neurodégénératives
GB201107985D0 (en) Process
HUP1100290A2 (en) Combination compositions for the treatment of proliferative diseases
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
HK1196953A1 (zh) 用於治療糖尿病的製劑
AU2012903365A0 (en) Compounds for the treatment of mTOR pathway related diseases
GB201119533D0 (en) Compounds for the treatment of neoplasia
GB201106970D0 (en) Compounds for the treatment of clostridium difficile-associated disease
GB201106972D0 (en) Compounds for the treatment of clostridium difficile-associated disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12705717

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12705717

Country of ref document: EP

Kind code of ref document: A2